Mature B-Cell Acute Lymphoblastic Leukemia

  • Reiji FukanoEmail author


Mature B-cell acute lymphoblastic leukemia (ALL), which is known as Burkitt leukemia, is included in Burkitt lymphoma according to the WHO classification. Approximately 80% of mature B-cell ALL is associated with t(8;14)(q24;q32). The Lymphoma Malignancy B and Berlin–Frankfurt–Munster studies have showed that intensive multiagent chemotherapy improves the outcome of mature B-cell ALL, and that the long-term event-free survival rate of advanced stage mature B-cell non-Hodgkin lymphoma (B-NHL), including mature B-cell leukemia, is 80–85%. However, the prognosis of relapsed or refractory B-NHL is poor. The short-term overall survival of patients with relapsed or refractory B-NHL has been reported to be approximately 20–30%, even though hematopoietic stem cell transplantation has been adopted. The efficacy of rituximab, an anti-CD20 antibody, has been established for adults with B-NHL. Recently, the safety and efficacy of rituximab for pediatric B-NHL has also been reported. Thus, it is expected that rituximab combined with chemotherapy will be established as the standard treatment for high-risk pediatric patients with B-NHL as well as for adults with B-NHL, and this therapy is believed to improve the outcome of mature B-cell leukemia.


Mature B-cell acute lymphoblastic leukemia Burkitt leukemia Burkitt lymphoma Mature B-cell non-Hodgkin lymphoma Rituximab 


  1. 1.
    Bene MC, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–6.PubMedPubMedCentralGoogle Scholar
  2. 2.
    Crist WM, et al. Immunologic markers in childhood acute lymphocytic leukemia. Semin Oncol. 1985;12(2):105–21.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Swerdlow SH, Harris NL. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2017.Google Scholar
  4. 4.
    Murphy SB. Classification, staging and end results of treatment of childhood non-Hodgkin’s lymphomas: dissimilarities from lymphomas in adults. Semin Oncol. 1980;7(3):332–9.PubMedPubMedCentralGoogle Scholar
  5. 5.
    Murphy SB, et al. Non-Hodgkin’s lymphomas of childhood: an analysis of the histology, staging, and response to treatment of 338 cases at a single institution. J Clin Oncol. 1989;7(2):186–93.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Sandlund JT. Should adolescents with NHL be treated as old children or young adults? Hematology Am Soc Hematol Educ Program. 2007:297–303.CrossRefGoogle Scholar
  7. 7.
    Hochberg J, et al. Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol. 2009;144(1):24–40.PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Bennett JM, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976;33(4):451–8.PubMedCrossRefPubMedCentralGoogle Scholar
  9. 9.
    Berger R, Bernheim A. Cytogenetic studies on Burkitt’s lymphoma-leukemia. Cancer Genet Cytogenet. 1982;7(3):231–44.PubMedCrossRefGoogle Scholar
  10. 10.
    Croce CM, Nowell PC. Molecular basis of human B cell neoplasia. Blood. 1985;65(1):1–7.PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol. 2009;19(6):366–76.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Lai JL, et al. Cytogenetic studies in 30 patients with Burkitt's lymphoma or L3 acute lymphoblastic leukemia with special reference to additional chromosome abnormalities. Ann Genet. 1989;32(1):26–32.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Johansson B, Mertens F, Mitelman F. Cytogenetic evolution patterns in non-Hodgkin's lymphoma. Blood. 1995;86(10):3905–14.PubMedCrossRefPubMedCentralGoogle Scholar
  14. 14.
    Poirel HA, et al. Specific cytogenetic abnormalities are associated with a significantly inferior outcome in children and adolescents with mature B-cell non-Hodgkin’s lymphoma: results of the FAB/LMB 96 international study. Leukemia. 2009;23(2):323–31.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Magrath IT, Ziegler JL. Bone marrow involvement in Burkitt’s lymphoma and its relationship to acute B-cell leukemia. Leuk Res. 1980;4(1):33–59.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Murphy SB, et al. Results of treatment of advanced-stage Burkitt's lymphoma and B cell (SIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated high-dose methotrexate and cytarabine. J Clin Oncol. 1986;4(12):1732–9.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Patte C, et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol. 1991;9(1):123–32.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Patte C, et al. Improved survival rate in children with stage III and IV B cell non-Hodgkin’s lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society. J Clin Oncol. 1986;4(8):1219–26.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Patte C, et al. The Societe Francaise d'Oncologie Pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97(11):3370–9.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Patte C, et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood. 2007;109(7):2773–80.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Cairo MS, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109(7):2736–43.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Reiter A, et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: A report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood. 1999;94(10):3294–306.PubMedGoogle Scholar
  23. 23.
    Seidemann K, et al. Primary mediastinal large B-cell lymphoma with sclerosis in pediatric and adolescent patients: treatment and results from three therapeutic studies of the Berlin-Frankfurt-Munster Group. J Clin Oncol. 2003;21(9):1782–9.PubMedCrossRefGoogle Scholar
  24. 24.
    Woessmann W, et al. The impact of the methotrexate administration schedule and dose in the treatment of children and adolescents with B-cell neoplasms: a report of the BFM Group Study NHL-BFM95. Blood. 2005;105(3):948–58.PubMedCrossRefGoogle Scholar
  25. 25.
    Salzburg J, et al. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin’s lymphoma differ by non-Hodgkin’s lymphoma subtype: a Berlin-Frankfurt-Munster Group Report. J Clin Oncol. 2007;25(25):3915–22.PubMedCrossRefGoogle Scholar
  26. 26.
    Murphy SB, Hustu HO. A randomized trial of combined modality therapy of childhood non-Hodgkin’s lymphoma. Cancer. 1980;45(4):630–7.PubMedCrossRefGoogle Scholar
  27. 27.
    Link MP, et al. Results of treatment of childhood localized non-Hodgkin's lymphoma with combination chemotherapy with or without radiotherapy. N Engl J Med. 1990;322(17):1169–74.PubMedCrossRefGoogle Scholar
  28. 28.
    Perkins SL, et al. B-Cell non-Hodgkin's lymphoma in children and adolescents: surface antigen expression and clinical implications for future targeted bioimmune therapy: a children’s cancer group report. Clin Adv Hematol Oncol. 2003;1(5):314–7.PubMedGoogle Scholar
  29. 29.
    Czuczman MS, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17(1):268–76.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Coiffier B, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–42.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Pfreundschuh M, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 2006;7(5):379–91.PubMedCrossRefPubMedCentralGoogle Scholar
  32. 32.
    Goldman S, et al. Rituximab with chemotherapy in children and adolescents with central nervous system and/or bone marrow-positive Burkitt lymphoma/leukaemia: a Children’s Oncology Group Report. Br J Haematol. 2014;167(3):394–401.PubMedPubMedCentralCrossRefGoogle Scholar
  33. 33.
    Meinhardt A, et al. Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin’s lymphoma and Burkitt leukemia. J Clin Oncol. 2010;28(19):3115–21.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Goldman S, et al. Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report. Leukemia. 2013;27(5):1174–7.PubMedCrossRefPubMedCentralGoogle Scholar
  35. 35.
    Goldman S, et al. Preliminary results of a reduced burden of therapy trial by incorporation of rituximab and intrathecal liposomal cytarabine in children, adolescents and young adults with intermediate (FAB Group B) and high risk (FAB Group C) mature B-cell lymphoma/leukemia. J Clin Oncol. 2016;34(15):10534.CrossRefGoogle Scholar
  36. 36.
    Philip T, et al. Curability of relapsed childhood B-cell non-Hodgkin's lymphoma after intensive first line therapy: a report from the Societe Francaise d'Oncologie Pediatrique. Blood. 1993;81(8):2003–6.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Jourdain A, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B-cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Societe Francaise des Cancers de l'Enfant study. Haematologica. 2015;100(6):810–7.PubMedPubMedCentralCrossRefGoogle Scholar
  38. 38.
    Anoop P, et al. Outcome of childhood relapsed or refractory mature B-cell non-Hodgkin lymphoma and acute lymphoblastic leukemia. Leuk Lymphoma. 2012;53(10):1882–8.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Fujita N, et al. The role of hematopoietic stem cell transplantation with relapsed or primary refractory childhood B-cell non-Hodgkin lymphoma and mature B-cell leukemia: a retrospective analysis of enrolled cases in Japan. Pediatr Blood Cancer. 2008;51(2):188–92.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Ladenstein R, et al. High-dose chemotherapy with autologous bone marrow rescue in children with poor-risk Burkitt’s lymphoma: a report from the European Lymphoma Bone Marrow Transplantation Registry. Blood. 1997;90(8):2921–30.PubMedCrossRefGoogle Scholar
  41. 41.
    Gross TG, et al. Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. Biol Blood Marrow Transplant. 2010;16(2):223–30.PubMedCrossRefGoogle Scholar
  42. 42.
    Cairo M, et al. Overall survival of children and adolescents with mature B cell non-Hodgkin lymphoma who had refractory or relapsed disease during or after treatment with FAB/LMB 96: A report from the FAB/LMB 96 study group. Br J Haematol. 2018;182(6):859–69.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Griffin TC, et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2009;52(2):177–81.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2020

Authors and Affiliations

  1. 1.Department of PediatricsYamaguchi University Graduate School of MedicineYamaguchiJapan

Personalised recommendations